Ashling Wahner

The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.

The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.

Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

The FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.

Rena D. Callahan, MD, discusses the current standards for breast cancer imaging modalities, the complexities of using bone biopsy, and the importance of continuing to study nonstandard imaging modalities to increase the accessibility of breast cancer imaging for metastatic disease.

The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.

Faith E. Davies, MD, discusses the overarching goals of the Multiple Myeloma Call-to-Action, unmet needs that this plan seeks to alleviate, and ways in which all medical professionals could adopt these tenets into their practice to achieve global change in the care of patients with multiple myeloma.

The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.

Overall response rates with bispecific antibody monotherapy in patients with extramedullary relapsed/refractory multiple myeloma were lower than ORRs observed across all patients with relapsed/refractory multiple myeloma included in a systematic review evaluating the efficacy of this class of agents in this difficult-to-treat population.

Naval G. Daver, MD, discusses the rationale for investigating uproleselan combinations in patients with acute myeloid leukemia, the current role of quizartinib in patients with FLT3-ITD–mutated disease, and potential future directions with both these agents in the AML field.

Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.

Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.

Guillermo Garcia-Manero, M, discusses key efficacy and safety findings from the COMMANDS trial; the significance of the FDA approval of luspatercept in patients with lower-risk MDS; and considerations for bringing this agent into clinical practice.

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with inoperable or metastatic hormone receptor–positive, HER2-low or HER2-negative breast cancer.

Howard S. Hochster, MD, highlights key updates in CRC research and management from the 2023 ASCO Annual Meeting, including findings from the phase 2/3 PROSPECT trial, long-term follow-up data from the phase 3 PRODIGE 23 trial, and results of the phase 3 NeoCol study.

Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.

John Seymour, AM, MBBS, FRACP, FAHMS, PhD, discusses the characteristics of patients with CLL who may benefit from FCR, how genetic testing can provide key insights into individual patient disease patterns, and treatment sequencing options after progression on FCR.

The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.

Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.

Yara Abdou, MD, discusses key updates in breast cancer research, including paradigm shifts on the horizon for trastuzumab deruxtecan, key data regarding capivasertib in the hormone receptor–positive, HER2-negative setting, and the importance of weighing the efficacy benefits of these agents with the risks for serious associated toxicities.

Sophia Rose O’Brien, MD, discusses the optimal uses for FDG PET/CT and FES PET/CT in patients with metastatic breast cancer; limitations of these imaging modalities to consider, particularly in patients with estrogen receptor-positive disease; and the potential advantages of using FDG assessment in patients with oligometastatic disease.

Millie Das, MD, highlights early efficacy signals with PARP inhibitors in patients with small cell lung cancer, how overall survival data from the phase 3 ADAURA trial confirm the efficacy of adjuvant osimertinib in patients with non–small cell lung cancer, and which patients may benefit most from immunotherapy as monotherapy or in combination with other agents.

Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.

Martin E. Gutierrez, MD, and Lori A. Leslie, MD, discuss common barriers to implementing CAR T-cell therapy programs, early successes that John Theurer Cancer Center in New Jersey has seen with outpatient CAR T-cell therapy administration, and developments on the horizon for administering this approach in solid tumors